



PLEASE NOTE: *This trial has been registered retrospectively.*

Trial Description

Title

ADOREG - development and establishment of a nationwide prospective register for Health Services Research in dermatologic oncology

Trial Acronym

ADOREG

URL of the trial

[---]*

Brief Summary in Lay Language

The aim of the project is a medical , information technology and organizational structure and operation of an online documentation system based on the applicable data protection regulations , in which all aspects and details of the treatment of dermatological tumors in clinical practice will be covered , stored in a central database as a prospective registry and evaluated with analysis programs for various scientific and project-related issues.

ADOREG is realized with the three sub- registers

- **Malignant Melanoma**
- **Epithelial tumors**
- **Actinic keratoses**

Brief Summary in Scientific Language

ADOREG is an electronic system / register for departments of skin cancer to enter all informations of health care and therapies of patients with skin cancer (Malignant Melanoma, Epithelial Tumors and Actinic Keratosis) to serve all informations for an academic evaluation.

Organizational Data

- DRKS-ID: **DRKS00006123**
- Date of Registration in DRKS: **2016/05/04**
- Date of Registration in Partner Registry or other Primary Registry: [---]*
- Investigator Sponsored/Initiated Trial (IST/IIT): **yes**
- Ethics Approval/Approval of the Ethics Committee: **Approved**
- (leading) Ethics Committee Nr.: **13-5359-BO , Ethik-Kommission der Medizinischen Fakultät der Universität Duisburg-Essen**



Secondary IDs

Health condition or Problem studied

- Free text: **In Pilotphase Malignant Melanoma from Stage IIB, after pilotphase Epithelial Skin Cancer and Actinic Keratosis**
- ICD10: **C43-C44 - Melanoma and other malignant neoplasms of skin**

Interventions/Observational Groups

- Arm 1: **prospective data collection in a register of patients with Skin Cancer:**
 - **Malignant Melanoma from Stage IIB (Pilotphase)**
 - **Epithelial Skin Cancer**
 - **Actinic Keratosis**

Characteristics

- Study Type: **Non-interventional**
- Study Type Non-Interventional: **Observational study**
- Allocation: **Single arm study**
- Blinding: [---]*
- Who is blinded: [---]*
- Control: **Uncontrolled/Single arm**
- Purpose: **Treatment**
- Assignment: **Single (group)**
- Phase: **N/A**
- Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **N/A**

Primary Outcome

Prospective informations about courses of treatments of patients with Malignant Melanoma from Stage IIB (Pilotphase) and also patients with epithelial Skin Cancer and Actinic Keratosis will begatherd via online portal ODM QuaSI. This is an unlimited register study.

Secondary Outcome



Process of Health Care and Therapy

Countries of recruitment

- DE **Germany**

Locations of Recruitment

- University Medical Center **Dermatologie, Essen**
- Medical Center **Dermatologie, Mannheim**
- University Medical Center **Dermatologie, Kiel**
- Medical Center **Dermatologie, Münster**
- Medical Center **Dermatologie, Mainz**
- Medical Center **Dermatologie, München**
- Medical Center **Dermatologie, Dresden**
- Medical Center **Dermatologie, Buxtehude**

Recruitment

- Planned/Actual: **Actual**
- (Anticipated or Actual) Date of First Enrollment: **2013/09/15**
- Target Sample Size: **20000**
- Monocenter/Multicenter trial: **Multicenter trial**
- National/International: **National**

Inclusion Criteria

- Gender: **Both, male and female**
- Minimum Age: **18 Years**
- Maximum Age: **80 Years**

Additional Inclusion Criteria

- **Malignant Melanoma from Stage IIB (Pilotphase)**
- **Epithelial Skin Cancer**
- **Actinic Keratosis**

Exclusion criteria



No sign / confirmation of Malignant Melanoma from Stage IIB, Epithelial Skin Cancers or Actinic Ceratosis

Addresses

■ Primary Sponsor

**Uniklinik Essen, Hautklinik
Mr. Prof. Dr. Dirk Schadendorf
Hufelandstr. 55
45122 Esseb
Germany**

Telephone: **+492017234342**

Fax: **+492017235935**

E-mail: **Dirk.Schadendorf at uk-essen.de**

URL: **<http://www.uk-essen.de/Hautklinik>**

■ Contact for Scientific Queries

**Uniklinik Essen, Hautklinik
Mr. Prof. Dr. Dirk Schadendorf
Hufelandstr. 55
45122 Esseb
Germany**

Telephone: **+492017234342**

Fax: **+492017235935**

E-mail: **Dirk.Schadendorf at uk-essen.de**

URL: **<http://www.uk-essen.de/Hautklinik>**

■ Contact for Public Queries

**Uniklinik Essen, Hautklinik
Mr. Prof. Dr. Dirk Schadendorf
Hufelandstr. 55
45122 Esseb
Germany**

Telephone: **+492017234342**

Fax: **+492017235935**

E-mail: **Dirk.Schadendorf at uk-essen.de**

URL: **<http://www.uk-essen.de/Hautklinik>**

Sources of Monetary or Material Support

■ Private sponsorship (foundations, study societies, etc.)

Uniklinik Essen, Hautklinik



Private sponsorship (foundations, study societies, etc.)

Uniklinik Essen, Hautklinik
Mr. Prof. Dr. Dirk Schadendorf
Hufelandstr. 55
45122 Essen
Germany

Telephone: **+492017234342**

Fax: **+492017235935**

E-mail: **Dirk.Schadendorf at uk-essen.de**

URL: **http://www.uk-essen.de/Hautklinik**

■ **Commercial (pharmaceutical industry, medical engineering industry, etc.)**

ONKODATAMED
Mr. Dr. Lutz Reimer
Friedenstr.58
15366 Neuhagen bei Berlin
Germany

Telephone: [---]*

Fax: [---]*

E-mail: [---]*

URL: [---]*

Status

- Recruitment Status: **Recruiting ongoing**
- Study Closing (LPLV): [---]*

Trial Publications, Results and other documents

* This entry means the parameter is not applicable or has not been set.

*** This entry means that data is not displayed due to insufficient data privacy clearing.